Key result
Sulfinpyrazone therapy in patients with prosthetic cardiac valves was associated with 0% thromboembolism when platelet survival time increased, compared to 31% when it failed to increase.
Why the study?
Does sulfinpyrazone prevent thromboembolism in patients with prosthetic cardiac valves and shortened platelet survival time?
Cohort (n=126)
Does sulfinpyrazone prevent thromboembolism in patients with prosthetic cardiac valves and shortened platelet survival time?
In patients with prosthetic cardiac valves and shortened platelet survival time, failure of sulfinpyrazone to increase platelet survival time is associated with a high risk of thromboembolism.
Answers are grounded in this paper and cite their sources.
Failure to increase platelet survival on sulfinpyrazone identifies high-risk patients; leaves open whether adjusting therapy reduces thromboembolism.
Platelet survival time (SURV) has correlated with thromboembolism in patients with prosthetic cardiac valves. Sulfinpyrazone increases SURV. SURV (autologous labeling with 51Chromium) was measured in 126 patients who had aortic or mitral valve replacement. These patients were followed prospectively. Ninety-four with shortened SURV received sulfinpyrazone; 32 with normal SURV were not treated with platelet suppressants. Eighty-seven patients were anticoagulated with warfarin--67 with shortened SURV and 20 with normal SURV. Eleven patients have had thromboembolism, and all had shortened SURV (2.4 +/- 0.08 days; average half-time +/- SEM; normal 3.7 +/- 0.03 days; n = 26) none had an increase of SURV with sulfinpyrazone (2.3 +/- 0.09 days). Of 83 patients with shortened SURV who did not have embolism, sulfinpyrazone increased SURV in 59 (71%) 2.6 +/- 0.05 to 2.9 +/- 0.06 days). Of 35 patients with shortened SURV who failed to increase SURV with sulfinpyrazone, 11 (31%) had embolism; none of 59 (0%) with an increase of SURV with sulfinpyrazone had thromboembolism. These results suggest that patients with thromboembolism after prosthetic cardiac valve replacement have shortened SURV and that patients treated with slufinpyrazone who have thromboembolism do not have an increased SURV.
No takes yet. Share an insight, caveat, or question.
Steele et al. (1979) conducted a cohort in Prosthetic cardiac valves (n=126). Sulfinpyrazone vs. Patients failing to increase platelet survival time was evaluated on Thromboembolism. Sulfinpyrazone therapy in patients with prosthetic cardiac valves was associated with 0% thromboembolism when platelet survival time increased, compared to 31% when it failed to increase.
Synapse has enriched 10 related papers. Consider them for comparative context: